CGTX Cognition Therapeutics, Inc.
Price Chart
Executive Summary
Cognition Therapeutics held a productive FDA meeting on May 20, 2026, to discuss Phase 2 SHIMMER study results for zervimesine (CT1812) in dementia with Lewy bodies (DLB) with psychosis. The company believes it has a path forward for a registrational program, with formal FDA minutes expected in June. This is a positive regulatory milestone for a clinical-stage biotech with a $115M market cap, but no definitive approval or data readout was announced.
Actionable Insight
The FDA meeting outcome is a positive catalyst for CGTX, reducing regulatory risk for the DLB psychosis program. Traders should watch for formal FDA minutes in June and any subsequent trial design details. The stock may see upward momentum on this news, but given the early stage and historical volatility, position sizing should account for binary risk.
Key Facts
- Productive FDA meeting on May 20, 2026, to discuss Phase 2 SHIMMER study results for zervimesine (CT1812) in DLB with psychosis.
- Company believes it has a path forward for a registrational program; formal FDA minutes expected in June.
- Zervimesine is an oral therapy targeting toxic oligomers; Phase 2 studies completed in DLB, mild-to-moderate Alzheimer's, and geographic atrophy.
- Backed by nearly $200 million in NIH and foundation grants.
- Market cap ~$115M; 90% analyst consensus bullish (2 Strong Buy, 7 Buy, 1 Hold).
Financial Impact
No financial data provided; clinical-stage company with no approved products or revenue.
Risk Factors
- Formal FDA minutes may include conditions or requirements that alter the registrational path.
- Clinical-stage biotech with no approved products; high execution risk and capital needs.
- Historical performance shows high volatility and mixed outcomes for prior reports on this ticker.
Market Snapshot
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3299218 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
|
Jun 4, 2026
10d ago
|
8-K
| $1.36 $1.29 | ▼ −5.15% | ▼ −2.55% | $1.21 (−11.03%) |
|
Jun 1, 2026
13d ago
|
Press Release
| $1.25 $1.35 | ▲ +8.00% | ▲ +7.86% | $1.21 (−3.20%) |
|
May 21, 2026
24d ago
|
Press Release
| $1.25 $1.26 | ▲ +0.80% | ▲ +0.35% | $1.21 (−3.20%) |
|
May 14, 2026
4w ago
|
Press Release
| $1.20 $1.14 | ▼ −5.00% | ▼ −3.77% | $1.21 (+0.83%) |
|
May 7, 2026
5w ago
|
8-K
| $1.21 $1.18 | ▼ −2.48% | ▼ −2.71% | $1.21 (+0.00%) |
|
Apr 16, 2026
8w ago
|
Insider Cluster
| $1.11 $1.19 | ▲ +7.21% | ▲ +5.99% | $1.21 (+9.01%) |
|
Mar 26, 2026
11w ago
|
Press Release
| $1.08 $0.7300 | ▼ −32.41% | ▼ −30.73% | $1.21 (+12.04%) |
|
Mar 23, 2026
11w ago
|
Press Release
| $1.13 $1.10 | ▼ −2.65% | ▼ −2.30% | $1.21 (+7.08%) |
|
Mar 17, 2026
12w ago
|
Press Release
| $1.15 $1.10 | ▼ −4.35% | ▼ −2.95% | $1.21 (+5.22%) |
|
Mar 2, 2026
14w ago
|
Press Release
| $1.06 $1.02 | ▼ −3.77% | ▼ −2.86% | $1.21 (+14.15%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access